MedPath

Eli Lilly CDR (CAD Hedged)

Eli Lilly CDR (CAD Hedged) logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
43K
Market Cap
$859.4B
Website
Introduction

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

Phase 1
Recruiting
Conditions
Hepatic Insufficiency
Healthy
Interventions
First Posted Date
2024-12-05
Last Posted Date
2025-04-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
48
Registration Number
NCT06719128
Locations
πŸ‡ΊπŸ‡Έ

Orange County Research Center, Lake Forest, California, United States

πŸ‡ΊπŸ‡Έ

Clinical Pharmacology of Miami, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

Orlando Clinical Research Center, Orlando, Florida, United States

and more 1 locations

A Study of LY4060874 in Healthy Participants

Phase 1
Recruiting
Conditions
Healthy Participants
Interventions
Drug: Placebo
First Posted Date
2024-11-29
Last Posted Date
2025-07-01
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
132
Registration Number
NCT06709820
Locations
πŸ‡ΊπŸ‡Έ

Fortrea, Inc., Dallas, Texas, United States

πŸ‡ΈπŸ‡¬

Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-11-26
Last Posted Date
2025-02-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
27
Registration Number
NCT06704763
Locations
πŸ‡ΊπŸ‡Έ

ICON, Salt Lake City, Utah, United States

A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-11-18
Last Posted Date
2025-06-24
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
86
Registration Number
NCT06692348
Locations
πŸ‡―πŸ‡΅

Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan

πŸ‡―πŸ‡΅

Sumida Hospital, Sumida-ku, Tokyo, Japan

πŸ‡―πŸ‡΅

Hakata Clinic, Fukuoka, Japan

A Study of LY4005130 in Healthy Participants

Phase 1
Recruiting
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2024-11-15
Last Posted Date
2025-02-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
140
Registration Number
NCT06690996
Locations
πŸ‡ΊπŸ‡Έ

Fortrea Clinical Research Unit, Dallas, Texas, United States

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Phase 2
Active, not recruiting
Conditions
Obesity
Overweight
Interventions
Drug: Placebo
First Posted Date
2024-11-12
Last Posted Date
2025-04-22
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
275
Registration Number
NCT06683508
Locations
πŸ‡ΊπŸ‡Έ

The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States

πŸ‡ΊπŸ‡Έ

HOPE Research Institute, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Headlands Research - Scottsdale, Scottsdale, Arizona, United States

and more 46 locations

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Phase 3
Recruiting
Conditions
Obesity
Overweight
Interventions
Drug: Placebo
First Posted Date
2024-11-04
Last Posted Date
2025-06-25
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
125
Registration Number
NCT06672939
Locations
πŸ‡ΊπŸ‡Έ

Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California, United States

πŸ‡ΊπŸ‡Έ

Yale School of Medicine - Yale Diabetes Center (YDC)) Trials, New Haven, Connecticut, United States

πŸ‡ΊπŸ‡Έ

Stamford Therapeutics Consortium, Stamford, Connecticut, United States

and more 37 locations

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Phase 3
Recruiting
Conditions
Obesity
Overweight
Interventions
Drug: Placebo
First Posted Date
2024-11-04
Last Posted Date
2025-06-25
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
125
Registration Number
NCT06672549
Locations
πŸ‡ΊπŸ‡Έ

Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California, United States

πŸ‡ΊπŸ‡Έ

Yale School of Medicine - Yale Diabetes Center (YDC)) Trials, New Haven, Connecticut, United States

πŸ‡ΊπŸ‡Έ

Stamford Therapeutics Consortium, Stamford, Connecticut, United States

and more 32 locations

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Phase 3
Active, not recruiting
Conditions
Obesity
Interventions
First Posted Date
2024-10-28
Last Posted Date
2025-04-27
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
800
Registration Number
NCT06662383
Locations
πŸ‡ΊπŸ‡Έ

Medical Advancement Centers of Arizona, Tempe, Arizona, United States

πŸ‡ΊπŸ‡Έ

Mary & Dick Allen Diabetes Center, Newport Beach, California, United States

πŸ‡ΊπŸ‡Έ

Artemis Institute for Clinical Research, San Diego, California, United States

and more 62 locations

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

Phase 1
Recruiting
Conditions
Alzheimer Disease
Healthy
Interventions
Drug: Placebo
First Posted Date
2024-10-24
Last Posted Date
2025-06-25
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
68
Registration Number
NCT06657768
Locations
πŸ‡ΊπŸ‡Έ

K2 Medical Research - The Villages, Lady Lake, Florida, United States

πŸ‡ΊπŸ‡Έ

K2 Medical Research, Maitland, Florida, United States

πŸ‡ΊπŸ‡Έ

Collaborative Neuroscience Network - CNS, Los Alamitos, California, United States

and more 4 locations
Β© Copyright 2025. All Rights Reserved by MedPath